ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

OMG! Tuesday 15 March: Summary of last week’s newsletter

Share On Facebook
share on Linkedin
Print

The OMG newsletter recommends at least 15 companies each month, using the writers’ experience of small caps to give you a winning edge. Last week they wrote about Johnson Service Group’ and Science in Sports. Read about these Opportunities 4 Material Gains!

©

Mid-week Tip

Profit set to bounce back at Johnson

Johnson Service Group (LSE: JSG)  are 116.4p , Mkt Cap £480m, which is higher than last week’s recommendation. It has had a tough time over the past two years. Hotel and catering linen hire is important to the business and that slumped during the initial lockdown. Subsequent restrictions have also held back the business – most recently the Omnicron-related restrictions in December and January. The hotel and catering operations are back to around 85% of pre-Covid levels and the recovery continues. Revenues will not get back to previous levels this year, but the operational gearing means that profit will be much higher. Costs are fixed, which will delay some of the pain. Management has also successfully implemented price rises to cover some of the cost increases. Of course, competitors will have the same cost pressures without the benefits of the productivity improvements from capital expenditure. The current expectations for 2022 appear achievable, but even if there are additional challenges during the year there is going to be a sharp recovery. The share price fell nearly 10% after the results were announced. The multiple is 16 times forecast earnings and that could fall to 13 in 2023. Johnson Service Group has net debt of £22.3m and Investec expects that to fall to £8.1m by the end of 2022 even after additional capital investment. There could be a return to dividend payments. This decline provides a buying opportunity

 

Results Preview

Performance kick

Science in Sports (LSE:SIS)  54.6p Mkt Cap £74.3mScience in Sport (SIS), founded in 1991 is a sports nutrition business that develops, manufactures, and markets innovative nutrition products aimed at the higher value end of the market to professional athletes, sports and fitness enthusiasts and the active lifestyle community. It reports finals to December 2021 this Wednesday. The Pre-Finals Trading update reported that on £60m turnover the EBITDA profit would improve to £2.2m. Its  Online sales had increased 40% to £35m overall- the Group’s digital platforms were up by 28%  with a  53% increase in third-party marketplace sites.   Online sales accounted for 56% of total sales and remain a critical driver of ongoing growth. It raised £4.5m at 37p in April 2020 to accelerate investment, and there is cash of around £5m. It’s taken a long time to gain this traction  which should lead to improving profitability. Longer term buy.

 

 Missing ingredient

Itaconix (LSE: ITX) 3.75p, Mkt Cap 3.5p. Since the emergency share placing at 1.1p in 2020 when £1.76m was raised the share price, in this proprietary plant-based polymer technology platform, bean-stalked to 17p in 2021. Founded in 2002, its innovative essential ingredients are used to improve the sustainability of everyday consumer products while adding a technical advantage. The 156% surge in 2020 revenue to $3.29m (but with a loss of $1.6m) turned out to be Covid  panic buying of its hygiene and detergent polymer/ingredients. This  ‘unsustainable’  boost was revealed in the 2021 interims as sales growth  returned to a more sedate pace 26% at $1.4m with a loss of $0.2m. Second half comparatives will be tougher. The sales strategy is characterised by Ignition, Traction, and Take-off.   This  year’s potential take-offs include  two dishwashing detergents which are already launched in the US and set to be launched in Europe. The 2021 trading update is set show total revenues at $2.6m and an increased loss. Cash is anticipated to be $0.7m. That will suffice for the time being but further fundraisings seem likely. A speculative buy on further weakness.

 

Reviews

views

DEST – 52p – Funding until partner secured 

OMIP – 6.25p – 4 Fans

MWE – 62p –  Russia withdrawal 

MEAL – 21p – Cash to reboot growth

IOF – 19.25p – Director buying 

BLV – 240p – Digital buy

NBI – 171p – Return to dividends

AMYT – $6.30 – FDA asks for more info on EB drug

GLAN – 77.5p – Arden trims forecast

ORPH – 15.5p – Additional capacity

KETL – 245p – New products 

DNL – 35.5p – No automatic reimbursement in Scotland

BILN – 257p – Painting acquisition

 

Finally:   Third World war anxiety and lower GDP growth with increasing Inflation and interest rates create conflicting  policy dilemmas  for the Chancellor mini-budget on Thursday the 24th of March.

 

OMG!  Opportunity for Massive Gains is a Premium Newsletter on ADVFN with two reports each week written by experienced small cap specialists. To get trips like this every week, sign up here.

 

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Plc. ADVFN Plc does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

Leave A Reply

 
Do you want to write for our Newspaper? Get in touch: newspaper@advfn.com